Future Oncology

Papers
(The H4-Index of Future Oncology is 29. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small-cell lung cancer112
Development of a model to predict the prognosis of esophageal carcinoma based on autophagy-related genes80
The SYK inhibitor: a novel agent for improved outcomes in relapsed/refractory diffuse large B-cell lymphoma66
Crosstalk Between Circrnas and the PI3K/AKT and/or MEK/ERK Signaling Pathways in Digestive Tract Malignancy Progression57
Radiofrequency ablation versus stereotactic body radiation therapy for hepatocellular carcinoma: a meta-regression56
The relationship between VDR polymorphisms and keratinocyte carcinomas: a systematic review and meta-analysis55
Correction50
A Multicenter, Phase Ib/II, Open-Label Study of Tivozanib with Durvalumab in Advanced Hepatocellular Carcinoma (DEDUCTIVE)49
Immunotherapy for Liposarcoma: Emerging Opportunities and Challenges49
A Phase III, Randomized, Open-Label Study (CONTACT-02) of Cabozantinib Plus Atezolizumab Versus Second Novel Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer49
Should One Use the Combination of Abiraterone and Poly(ADP-ribose) Polymerase Inhibitors as First-Line Therapy for all Patients with Metastatic Castration-Resistant Prostate Cancer?48
Results of a survey study on health professionals’ perceptions of tumor boards in Brazil48
Cost–effectiveness of aumolertinib as first-line treatment for EGFR-mutated advanced nonsmall-cell lung cancer47
Diagnosis of chondrosarcoma in a noninvasive way using volatile organic compounds in exhaled breath: a pilot study46
Sex bias phenomenon in oral cancer: an insight38
Barriers and solutions for healthcare professionals to involve patients as partners in oncology research: Project RISE37
The prognostic value of radiomic features in liver-limited metastatic colorectal cancer patients from the TRIBE2 study34
Treatment patterns and clinical outcomes in metastatic urothelial carcinoma: a German retrospective real-world analysis33
Systematic literature review of the epidemiology of neurotrophic tyrosine receptor kinase positive solid tumor sites33
Matching-adjusted indirect comparison of selpercatinib and pralsetinib in RET fusion–positive non–small cell lung cancer32
Impact of social determinants of health on treatment patterns and outcomes in multiple myeloma32
Real-world treatment patterns and genetic testing in a metastatic castration-resistant prostate cancer setting in Europe31
Prevalence of homologous recombination biomarkers in multiple tumor types: an observational study31
Enzalutamide with standard first-line therapy for metastatic hormone-sensitive prostate cancer: a plain language summary of the ENZAMET trial (ANZUP 1304)31
Brain Injury after Cranial Radiotherapy Combined with Immunotherapy for Brain Metastases in Lung Cancer: A Retrospective Study31
RELAY: safety and efficacy of ramucirumab plus erlotinib in elderly Japanese patients with metastatic EGFR -mutated NSCLC30
Real-world outcomes in non-small-cell lung cancer patients with MET Exon 14 skipping mutation and brain metastases treated with capmatinib29
Sacituzumab Govitecan: Past, Present and Future of a New Antibody–Drug Conjugate and Future Horizon29
In -Class Transition from Bortezomib-Based Therapy to IRd is an Effective Approach in Newly Diagnosed Multiple Myeloma29
0.15122413635254